Zobrazeno 1 - 10
of 870
pro vyhledávání: '"Durant ST"'
Autor:
Dibitetto D; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156, Milan, Italy. diego.dibitetto@marionegri.it., Liptay M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Vivalda F; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Dogan H; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Gogola E; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., González Fernández M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Duarte A; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Schmid JA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Decollogny M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Francica P; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Przetocka S; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Durant ST; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Forment JV; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Klebic I; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Siffert M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Kousholt AN; Oncode Institute, Amsterdam, The Netherlands.; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Marti NA; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Dettwiler M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Sørensen CS; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Tille JC; Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Undurraga M; Division of Gynecology, Department of Pediatrics and Gynecology, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Labidi-Galy I; Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Lopes M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Sartori AA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch.
Publikováno v:
Nature communications [Nat Commun] 2024 May 24; Vol. 15 (1), pp. 4430. Date of Electronic Publication: 2024 May 24.
Autor:
Pike KG; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hunt TA; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Benstead D; Pharmaceutical Sciences, AstraZeneca, Silk Road Business Park, Macclesfield SK10 2NA, U.K., Cadogan E; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chen K; Innovation Center China, Asia & Emerging Markets iMED, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China., Cook CR; Pharmaceutical Sciences, AstraZeneca, Silk Road Business Park, Macclesfield SK10 2NA, U.K., Colclough N; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Deng C; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Durant ST; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Goldberg K; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Liu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Liu Z; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Nissink JWM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Pang C; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Pass M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Robb GR; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Roberts C; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Schou M; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Steward O; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Sykes A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Yan Y; Innovation Center China, Asia & Emerging Markets iMED, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China., Zhai B; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Zheng L; Innovation Center China, Asia & Emerging Markets iMED, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 3090-3111. Date of Electronic Publication: 2024 Feb 02.
Autor:
Tew BY; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California., Kalfa AJ; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California., Yang Z; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California., Hurth KM; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California., Simon T; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California., Abnoosian E; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California., Durant ST; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hamerlik P; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Salhia B; Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4492-4503.
Autor:
Li H; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Liu Y; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Xiao Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Wilson CN; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Bai HJ; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Jones MD; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., Wang S; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712., DeVore JE; Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin, Austin, TX 78723., Maier EY; Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin, Austin, TX 78723., Durant ST; Early Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.; Evotec UK, Oxfordshire OX14 4RZ, England, UK., Boufraqech M; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892., Weyemi U; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.; Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Feb 07; Vol. 120 (6), pp. e2212072120. Date of Electronic Publication: 2023 Feb 01.
Autor:
Davis SL; University of Colorado Cancer Center, Aurora, CO, USA. Sarah.Davis@cuanschutz.edu., Hartman SJ; University of Colorado Cancer Center, Aurora, CO, USA., Bagby SM; University of Colorado Cancer Center, Aurora, CO, USA., Schlaepfer M; University of Colorado Cancer Center, Aurora, CO, USA., Yacob BW; University of Colorado Cancer Center, Aurora, CO, USA., Tse T; University of Colorado Cancer Center, Aurora, CO, USA., Simmons DM; University of Colorado Cancer Center, Aurora, CO, USA., Diamond JR; University of Colorado Cancer Center, Aurora, CO, USA., Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA., Leal AD; University of Colorado Cancer Center, Aurora, CO, USA., Cadogan EB; AstraZeneca, Cambridge, UK., Hughes GD; AstraZeneca, Cambridge, UK., Durant ST; AstraZeneca, Cambridge, UK., Messersmith WA; University of Colorado Cancer Center, Aurora, CO, USA., Pitts TM; University of Colorado Cancer Center, Aurora, CO, USA.
Publikováno v:
BMC cancer [BMC Cancer] 2022 Oct 29; Vol. 22 (1), pp. 1107. Date of Electronic Publication: 2022 Oct 29.
Autor:
Koneru B; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Farooqi A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Nguyen TH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Chen WH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Hindle A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Eslinger C; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Makena MR; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Burrow TA; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Wilson J; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Smith A; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Pilla Reddy V; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge SG8 6EE, UK., Cadogan E; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Durant ST; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Reynolds CP; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. patrick.reynolds@ttuhsc.edu.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Publikováno v:
Science translational medicine [Sci Transl Med] 2021 Aug 18; Vol. 13 (607).
Autor:
Exell, JC, Thompson, MJ, Finger, LD, Shaw, SJ, Debreczeni, J, Ward, TA, McWhirter, C, Siöberg, CLB, Molina, DM, Abbott, WM, Jones, CD, Nissink, JWM, Durant, ST, Grasby, JA
The structure-specific nuclease human flap endonuclease-1 (hFEN1) plays a key role in DNA replication and repair and may be of interest as an oncology target. We present the crystal structure of inhibitor-bound hFEN1, which shows a cyclic N-hydroxyur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::ae4b5d436c9147afb2e3326fcda76a03
https://eprints.whiterose.ac.uk/118189/1/emss-68537.pdf
https://eprints.whiterose.ac.uk/118189/1/emss-68537.pdf
Autor:
Zhang, Peipei1 (AUTHOR), Zhang, Weiguang1 (AUTHOR), Hong, Zhinuan1 (AUTHOR), Jiang, Junfei1 (AUTHOR), Wu, Ningzi1 (AUTHOR), Lin, Jihong2 (AUTHOR) ljh060@fjmu.edu.cn, Kang, Mingqiang1,2,3,4 (AUTHOR) mingqiang_kang@163.com
Publikováno v:
Scientific Reports. 11/7/2024, Vol. 14 Issue 1, p1-15. 15p.
Autor:
Zhang, Yihan1,2,3 (AUTHOR), Sun, Changning1,2,3 (AUTHOR), Ma, Leina1,2,3 (AUTHOR), Xiao, Guokai1,2,3 (AUTHOR), Gu, Yuchao1,2,3 (AUTHOR) guych@126.com, Yu, Wengong1,2,3 (AUTHOR) yuwg66@ouc.edu.cn
Publikováno v:
Clinical & Translational Medicine. Oct2024, Vol. 14 Issue 10, p1-21. 21p.
Autor:
Lei, Wenyang1, Yu, Wenting1, Zhong, Yu1, Li, Ti1, Xiao, Hongjun1 xhjent_whxh@hust.edu.cn, Zong, Shimin1 2018xh0090@hust.edu.cn
Publikováno v:
Oncologie (De Gruyter). Sep2024, Vol. 26 Issue 5, p711-720. 10p.